Answers are grounded in this paper and cite their sources.
Observational study demonstrates robust immunogenicity and minimal hepatic changes in vaccinated volunteers, highlighting a favorable vaccine safety profile.
COVID-19 is caused by the SARS-CoV-2 coronavirus. Vaccine development was essential for reducing hospitalizations and mortality during the pandemic. In Brazil, the ChAdOx1-S/nCoV-19 (AstraZeneca) vaccine was widely administered during the initial phase of the national immunization campaign. Despite a well-established safety profile, continuous surveillance of adverse events remains important. Mild adverse reactions occurred more frequently after the first dose and were generally self-limiting. The vaccine induced a strong IgG antibody response, demonstrating robust immunogenicity while producing minimal changes in liver function parameters. These findings support the favorable safety, tolerability, and immunogenic profile of the ChAdOx1-S/nCoV-19 vaccine in this population.
No takes yet. Share an insight, caveat, or question.
Coelho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: